Gala Therapeutics

Gala Therapeutics, Inc. is a medical device company focused on developing innovative treatments for pulmonary diseases, specifically chronic bronchitis. The company operates in the healthcare sector, targeting patients suffering from chronic bronchitis, a condition characterized by excess mucus production and persistent cough. Gala Therapeutics' flagship product, RheOx, is a bronchoscopic therapy that utilizes non-thermal pulsed electric fields to reduce mucus-producing cells in the airways, thereby improving patients' quality of life. The procedure is minimally invasive and can be performed by a single operator, making it a convenient option for both patients and healthcare providers. The company generates revenue through the sale of its RheOx system and related services. Gala Therapeutics is currently conducting clinical studies to further validate the efficacy and safety of its technology. The market for chronic bronchitis treatment is substantial, with approximately 15 million people affected in Europe and 9 million in the United States. Gala Therapeutics aims to capture a significant share of this market by offering a unique and effective solution for a condition that has limited treatment options.

Keywords: pulmonary disease, chronic bronchitis, medical device, RheOx, non-thermal pulsed electric fields, bronchoscopic therapy, minimally invasive, healthcare, clinical studies, mucus reduction.